These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30528642)

  • 1. Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk.
    Alonso-Troncoso I; Carollo-Limeres C; Rios-Prego M; Guler I; Cadarso-Suárez C; F-Mariño A
    Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(6):376-384. PubMed ID: 30528642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?
    Doggrell SA
    Rev Recent Clin Trials; 2015; 10(1):68-77. PubMed ID: 25881636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort.
    Mirani M; Favacchio G; Serone E; Lucisano G; Rossi MC; Berra CC
    Pharmacol Res; 2018 Nov; 137():270-279. PubMed ID: 30213563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is treatment with liraglutide efficient?
    Mezquita Raya P; Reyes García R
    Endocrinol Nutr; 2014 Apr; 61(4):202-8. PubMed ID: 24071060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.
    Bouchi R; Nakano Y; Fukuda T; Takeuchi T; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Endocr J; 2017 Mar; 64(3):269-281. PubMed ID: 27916783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial.
    de Wit HM; Vervoort GM; Jansen HJ; de Galan BE; Tack CJ
    J Intern Med; 2016 Mar; 279(3):283-92. PubMed ID: 26553486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.
    Russo GT; Labate AM; Giandalia A; Romeo EL; Villari P; Alibrandi A; Perdichizzi G; Cucinotta D
    J Endocrinol Invest; 2015 Jan; 38(1):81-9. PubMed ID: 25173876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.
    Gomez-Peralta F; Lecube A; Fernández-Mariño A; Alonso Troncoso I; Morales C; Morales-Pérez FM; Guler I; Cadarso-Suárez C
    Diabet Med; 2018 Nov; 35(11):1605-1612. PubMed ID: 29943854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.
    Lapolla A; Berra C; Boemi M; Bossi AC; Candido R; Di Cianni G; Frontoni S; Genovese S; Ponzani P; Provenzano V; Russo GT; Sciangula L; Simioni N; Bette C; Nicolucci A;
    Adv Ther; 2018 Feb; 35(2):243-253. PubMed ID: 29270781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].
    Giglio RV; Patti AM; Nikolic D; Castellino G; Noto M; Parrino A; Montalto G; Rizzo M
    G Ital Cardiol (Rome); 2016 Apr; 17(4):253-8. PubMed ID: 27093208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
    Madsbad S
    Expert Rev Cardiovasc Ther; 2019 May; 17(5):377-387. PubMed ID: 31055989
    [No Abstract]   [Full Text] [Related]  

  • 12. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.
    Fadini GP; Simioni N; Frison V; Dal Pos M; Bettio M; Rocchini P; Avogaro A
    Acta Diabetol; 2013 Dec; 50(6):943-9. PubMed ID: 23754673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
    Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.
    Guthrie R
    Postgrad Med; 2018 Mar; 130(2):154-158. PubMed ID: 29350569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
    Verma S; Bhatt DL; Bain SC; Buse JB; Mann JFE; Marso SP; Nauck MA; Poulter NR; Pratley RE; Zinman B; Michelsen MM; Monk Fries T; Rasmussen S; Leiter LA;
    Circulation; 2018 May; 137(20):2179-2183. PubMed ID: 29760228
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness and safety of liraglutide after three years of treatment.
    Ponzani P; Scardapane M; Nicolucci A; Rossi MC
    Minerva Endocrinol; 2016 Mar; 41(1):35-42. PubMed ID: 26878560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
    Olšovský J
    Vnitr Lek; 2016; 62(7-8):613-5. PubMed ID: 27627086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.
    Masmiquel L; Leiter LA; Vidal J; Bain S; Petrie J; Franek E; Raz I; Comlekci A; Jacob S; van Gaal L; Baeres FM; Marso SP; Eriksson M;
    Cardiovasc Diabetol; 2016 Feb; 15():29. PubMed ID: 26864124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2.
    de Luis DA; Ovalle HF; Soto GD; Izaola O; de la Fuente B; Romero E
    J Investig Med; 2014 Feb; 62(2):324-7. PubMed ID: 24322329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.